130 related articles for article (PubMed ID: 36477980)
1. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
[TBL] [Abstract][Full Text] [Related]
2. Improving colonoscopy prioritisation and promoting the National Bowel Cancer Screening Program: keys to reducing bowel cancer burden.
Grogan P; He E; Pockney P
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36918394
[TBL] [Abstract][Full Text] [Related]
3. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
6. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
[TBL] [Abstract][Full Text] [Related]
7. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
8. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
[TBL] [Abstract][Full Text] [Related]
9. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
[TBL] [Abstract][Full Text] [Related]
10. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
[TBL] [Abstract][Full Text] [Related]
13. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
[TBL] [Abstract][Full Text] [Related]
14. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
Ee H; St John J
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
[TBL] [Abstract][Full Text] [Related]
15. Realized impact of COVID-19 related disruptions on the National Bowel Cancer Screening Program.
Irwin MP; Dutta T; Jambor MA; Morgan MJ; Turner CE; Liang Y
ANZ J Surg; 2024 Feb; ():. PubMed ID: 38345127
[TBL] [Abstract][Full Text] [Related]
16. Screening colonoscopy in Australia.
Singh R; Mangira D; Kawano H; Matsuda T
Dig Endosc; 2015 Apr; 27 Suppl 1():30-4. PubMed ID: 25523496
[TBL] [Abstract][Full Text] [Related]
17. Initial impact of Australia's National Bowel Cancer Screening Program.
Ananda SS; McLaughlin SJ; Chen F; Hayes IP; Hunter AA; Skinner IJ; Steel MC; Jones IT; Hastie IA; Rieger NA; Shedda S; Compston DJ; Gibbs P
Med J Aust; 2009 Oct; 191(7):378-81. PubMed ID: 19807627
[TBL] [Abstract][Full Text] [Related]
18. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
19. Impact of a mass media campaign on participation rates in a National Bowel Cancer Screening Program: a field experiment.
Durkin SJ; Broun K; Spittal MJ; Wakefield MA
BMJ Open; 2019 Jan; 9(1):e024267. PubMed ID: 30813110
[TBL] [Abstract][Full Text] [Related]
20. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
